Tumor lysis syndrome (TLS) is an oncologic emergency that is characterized by numerous metabolic abnormalities, including hyperuricemic nephropathy, hyperphosphatemia, hypocalcemia, hyperkalemia and increased serum creatinine. This syndrome is common for tumors with rapid cell turnover and growth rates, and for bulky tumors with high sensitivity to anti-neoplastic treatments. Hence, TLS is a well-recognized clinical problem in hematologic malignancies. TLS is rarely observed to be induced in solid tumors by chemotherapy. Herein we present the second case of TLS that developed during radiotherapy in a patient with non-small cell lung cancer. TLS may also occur spontaneously and/or in other types of tumor that have a high proliferative rate, a large tumor burden or high sensitivity to cytotoxic therapy (6,7). The occurrence of TLS in solid tumors is relatively rare, but this malady has a high mortality rate. TLS is likely a consequence of less pre-emptive prophylaxis and reduced awareness of the occurrence of this problem in solid tumors. We report here on a case of TLS in a patient with non-small cell lung cancer and it occurred during radiotherapy. Sadly, the patient died despite undergoing hemodialysis.
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Tumor lysis syndrome (TLS) is an oncologic emergency. It is characterized by a group of metabolic derangements that are caused by the massive and abrupt release of cellular components into the blood after the rapid lysis of malignant cells (1) . The release of intracellular metabolites, including nucleic acids, proteins, phosphorus and potassium, can overwhelm the normal homeostatic mechanisms and this potentially leads to hyperuricemia, hyperkalemia, hyperphosphatemia, hypocalcemia and uremia (2) (3) (4) (5) . TLS is most frequently observed in patients with hematologic malignancies such as myeloproliferative disease, acute leukemia and highgrade non-Hodgkin's lymphoma, and especially Burkitt's lymphoma after the initiation of cytotoxic therapy, although TLS may also occur spontaneously and/or in other types of tumor that have a high proliferative rate, a large tumor burden or high sensitivity to cytotoxic therapy (6, 7) . The occurrence of TLS in solid tumors is relatively rare, but this malady has a high mortality rate. TLS is likely a consequence of less pre-emptive prophylaxis and reduced awareness of the occurrence of this problem in solid tumors. We report here on a case of TLS in a patient with non-small cell lung cancer and it occurred during radiotherapy. Sadly, the patient died despite undergoing hemodialysis. In this case, we thought the decrease in urine volume and the lab findings of TLS were caused by radiotherapy, but not by tumor progression itself because the tumor's size wasn't bulky or growing rapid enough to cause TLS. Further, these findings of TLS were seen immediately after radiotherapy, so we concluded that the cause of TLS was radiotherapy. The present case is the 2nd reported case of TLS that developed during radiotherapy in a patient with non-small cell lung cancer. The first case was described in 2008 in a patient with non-small cell lung cancer after receiving radiotherapy of 6 Gy (10).
The potential risk factors for TLS in solid tumors include a high turnover burden with a metastatic presentation, elevated levels of serum lactate dehydrogenase and uric acid, the response to anti-neoplastic treatment, pre-existing renal insufficiency, treatment with nephrotoxic agents and underlying problems, such as infections and intravascular volume depletion (7, 9, (11) (12) (13) . Because renal clearance is the primary method of eliminating most toxic products released into the circulation, aggressive hydration before and during treatment in high-risk patients is the mainstay of prevention.
The mortality rate for patients with solid tumors and TLS appears to be higher than that reported for TLS following treatment of hematologic malignances. This high mortality rate of solid tumor patients with TLS may be explained by the lack of prophylactic measures that are usually implemented before the start of chemotherapy for hematologic malignancies.
Contrary to hematologic malignancies, TLS in solid tumors can occur several days to weeks after treatment. Thus, awareness of the possibility of TLS in solid tumors, alertness and timely laboratory work-ups are essential for high-risk patients.
Frequent laboratory evaluations with a complete blood count and assessing the serum sodium, potassium, chloride, bicarbonate, calcium, phosphorus, uric acid and creatinine, and urine analysis before and during treatment are important for the early detection of TLS.
We have presented a rare case of TLS that was induced by radiotherapy in a patient with non-small cell lung cancer.
Whether or not a patient has a solid tumor and/or is treated by radiotherapy, this type of patient should be carefully observed because of the substantial risk for TLS.
